Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, highlights the importance of the Phase Ib/II ELECTRA trial (NCT05386108), which explores new treatment combinations for patients with HER2-positive, HR-positive (HR+/HER2+) breast cancer with CNS metastases. Though less common in this population compared to triple-negative or HER2-positive cases, CNS metastases carry a poor prognosis. The combination of abemaciclib and elacestrant, both capable of crossing the blood-brain barrier, offers a promising therapeutic approach for this difficult-to-treat condition. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
